Stelara® Biosimilar Updates: Settlement of IPR and FDA Review of Proposed Biosimilar
JD Supra Law
MARCH 7, 2024
The parties announced in a press release that their settlement and license agreement allows Biocon to commercialize Bmab 1200, its proposed biosimilar to Stelara® (ustekinumab), in the U.S. by February 2025, subject to FDA approval. By: Venable LLP
Let's personalize your content